Clinical Trial: Association between minimal residual disease and relapse after treatment for acute myeloid leukemia: A study based on multimodal CRISPR-based high-sensitivity biosensor development and real-time detection of minimal residual disease for early warning of acute myeloid leukemia relapse (China)

China, Aug. 31 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Association between minimal residual disease and relapse after treatment for acute myeloid leukemia: A study based on multimodal CRISPR-based high-sensitivity biosensor development and real-time detection of minimal residual disease for early warning of acute myeloid leukemia relapse'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600131143

Registration Time: 2026/08/28

Type: Diagnostic test

Primary Sponsor: Peking University Shenzhen Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=337115

Published by HT Digital Content Services with permission ...